Pharmaceutical heavyweight Mylan, the latest poster child for drug-industry greed, finally stuck up for itself Thursday. It argued that “the system,” not avarice, was to blame for the company jacking up the price of EpiPens, a common (and life-saving ...
Matt Levine is a Bloomberg View columnist. He was an editor of Dealbreaker, an investment banker at Goldman Sachs, a mergers and acquisitions lawyer at Wachtell, Lipton, Rosen & Katz and a clerk for the U.S.
GDP UP 1.1 PERCENT: U.S. GDP grew 1.1 percent in the second quarter of 2016, the Commerce Department reported today.The growth rate was lower than an initial estimate of 1.2 percent but higher than the first quarter of 2016's 0.8 percent.
Ridesharing app Uber may be enjoying brisk business as it expands around the globe, but the company isn't making money as a result.
Here are Friday's top research calls, including downgrades for Burlington Stores, Dollar General, Dollar Tree and Viacom. TheStreet Staff.